UBS AM’s OptimizeRx OPRX Stock Holding History

UBS AM’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.38K	Hold	940	–	–	﹤0.01%	3387
2026 Q1	$5.9K	Buy	940 +301	+47%	+$2.79K	﹤0.01%	3428
2025 Q4	$7.83K	Buy	+639	New	+$10.4K	﹤0.01%	2900
2024 Q4	–	Sell	-310,000	Closed	-$2.39M	–	2734
2024 Q3	$2.39M	Hold	310,000	–	–	﹤0.01%	1951
2024 Q2	$3.1M	Buy	+310,000	New	+$3.41M	﹤0.01%	1758
2022 Q3	–	Sell	-8,262	Closed	-$226K	–	2765
2022 Q2	$226K	Hold	8,262	–	–	﹤0.01%	2557
2022 Q1	$312K	Sell	8,262 -5,078	-38%	-$225K	﹤0.01%	2586
2021 Q4	$829K	Buy	13,340 +3,305	+33%	+$250K	﹤0.01%	2306
2021 Q3	$858K	Buy	10,035 +233	+2%	+$14.6K	﹤0.01%	2251
2021 Q2	$607K	Buy	+9,802	New	+$499K	﹤0.01%	2452

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $380M AUM 20.01% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

UBS AM's OPRX Position: Q2 2026 in Review

UBS AM held its OptimizeRx (OPRX) position steady in Q2 2026 at 940 shares worth $5.38K. The position accounts for ﹤0.01% of the portfolio, ranked #3387.

UBS AM first reported a position in OPRX in Q2 2021 and has held it in 10 quarters since. The position peaked at $3.1M in Q2 2024. 113 funds tracked by Wall St. Rank hold OPRX as of Q2 2026.

UBS AM held 940 shares of OptimizeRx worth $5.38K as of Q2 2026.
UBS AM left its OptimizeRx share count unchanged in Q2 2026.
OptimizeRx made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3387 holding.
UBS AM first reported a position in OptimizeRx in Q2 2021 and has held it in 10 quarters since.
UBS AM's OptimizeRx position peaked at $3.1M in Q2 2024.
113 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.